Subsection 9: Cancer treatment activities

For intensive chemotherapy leading to a foreseeable aplasia of more than eight days, the health establishment must have, in application of 3° of article R. 6123-94-2, during the treatment period, a permanent on-site medical presence: 1° For the holder of mention B, a specialised qualified doctor able to intervene twenty-four hours a day. A qualified doctor specialising in oncology-haematology or haematology with experience in the management of long-term aplasias is…

I.-The holder of the systemic cancer drug treatment authorisation is organised in such a way that, in order to guarantee continuity of care for the patient, the following information can be communicated: 1° To the patient and to the patient’s treating doctor, information on how to deal with the most frequent foreseeable situations relating to the patient’s treatment requiring urgent medical advice; 2° To the patient or to the doctor…

The authorisation holder has an organisation enabling it to record in writing, in order to ensure traceability, referrals of patients for the continuation of systemic cancer drug treatments close to their home within the framework of an association mentioned in Article R. 6123-90-1 and any initial prescriptions for significant changes in treatment made within this framework by advanced consultations or teleconsultations in application of the last paragraph of Article R….

I.-Health establishments authorised for interventional medicine, surgery or radiology and holders of authorisations for medical care and rehabilitation or home hospitalisation, applying systemic cancer drug treatments under the conditions set out in 1° of II of article R. 6123-90-1, have at least one practitioner with a university degree in continuing medical education or certified training in oncology, or who can demonstrate experience in administering specific cancer drug treatments. For hospital…